Renewal of licensing fee for the transgenic mouse strain, B-hIL2RA

The MIB is conducting pre-clinical research on photoimmunotherapy (PIT), a targeted treatment approach that uses light activation to destroy specific cells. One area of this research focuses on IL2RA, a protein expressed on regulatory T cells (Tregs). These cells can reduce the immune system’s ability to respond effectively to cancer. The objective of this work is to selectively eliminate IL2RA-expressing Tregs in order to improve anti-cancer immune responses. 

To support this research, MIB uses a transgenic mouse strain known as B-hIL2RA, which expresses the human form of IL2RA rather than the mouse form. Use of this model is essential because it enables evaluation of the same treatment materials, including antibodies, that are intended for future human application. As a result, this mouse strain has proven invaluable in the MIB’s ongoing research program. 

The MIB is requesting to renew a licensing fee for transgenic mice, B-hIL2RA. B-hIL2RA transgenic mice.